On May 26, 2017 Aduro Biotech, Inc. (NASDAQ:ADRO) reported that the Aduro management team will host an investor event with special guest speaker Jason J. Luke, M.D., FACP, Assistant Professor of Medicine at the University of Chicago and a principal investigator for the Phase 1 dose-escalation trial of ADU-S100 in patients with advanced/metastatic solid tumors or lymphomas (Press release, Aduro Biotech, MAY 26, 2017, View Source [SID1234519298]). This event will take place in conjunction with the 2017 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting in Chicago, IL on Saturday June 3, 2017, at 6:00 a.m. Central Time. Schedule your 30 min Free 1stOncology Demo! Dr. Luke is a clinical investigator and a medical oncologist whose research focuses on translational therapeutic advances for melanoma and early phase drug development, particularly immunotherapy.
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
To access the live webcast and subsequent archived recording of this and other company presentations, please visit the investor section of Aduro’s website at www.aduro.com.